GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
BHP Shares Fall as Jansen Potash Project Costs Surge 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Google Gemini Co-Lead Noam Shazeer Leaves for OpenAI Amid AI Talent Race 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Trump Says Anthropic No Longer Seen as National Security Threat 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
CAMBRIDGE, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the 34th Annual J.P. Morgan Healthcare Conference in San Francisco. Chairman of the Board of Directors Sandford D. Smith is scheduled to present on Thursday, January 14, 2016 at 8:00 a.m. PST (11:00 a.m. EST). Mr. Smith will also introduce Aegerion’s newly appointed Chief Executive Officer, Mary Szela.
The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the “Investors” section of Aegerion’s website, www.aegerion.com.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Associate Director, Investor Relations 857-242-5024
